Technology area: Biotechnology & Pharmaceuticals
87 pending office actions • 53 clients • 83 examiners • 57 art units • 0 of 87 (0%) have an AI response strategy ready
CHOATE, HALL & STEWART LLP handles Biotechnology & Pharmaceuticals matters across 6127 career applications and has 86 pending office actions. The profile combines a broad application base with a material active docket, making continued portfolio-level monitoring relevant.
The resolved allowance rate is 76.41%, and the average office actions per allowance is 3.57. The allowance rate supplies a historical resolution measure, while the action average indicates repeated examination activity in matters that ultimately reached allowance. Practitioners can use both figures when evaluating response planning, prosecution budgets, and the value of preserving fallback claim positions.
Based on the USPTO statutory response window for each pending office action. 33 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 33 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 4 (5%) |
| §103 only | 14 (16%) |
| §102 only | 5 (6%) |
| §112 only | 4 (5%) |
| Double-patenting + other | 18 (21%) |
| Multi-statute (no §101) | 39 (45%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALES, JOSEPHINE MARIA | 2 | 28.8% | +34.6% |
| AULAKH, CHARANJIT | 2 | 80.7% | -14.5% |
| FRUMKIN, JESSE P | 2 | 69.9% | +47.7% |
| PHAM, KHAI QUYNH TIEN | 2 | 0.0% | +0.0% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
| FERGUSON SAMRETH, MARISSA LIANA | 1 | 69.9% | +11.0% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| YANG, JIANXUN | 1 | 74.3% | +19.1% |
| KONVES, ADRIANNA N | 1 | 76.3% | +14.7% |
| TRAN, SUSAN T | 1 | 63.0% | +34.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710074 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | AULAKH, CHARANJIT | — |
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800932 | SYSTEMS AND METHODS FOR LIVE FISH TISSUE PRESERVATION | TICHY, JENNIFER M.H. | 81d overdue |
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ROSENTHAL, ANDREW S | 70d overdue |
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18034139 | TRANSDERMAL DELIVERY | BOSWORTH, KAMI A | 49d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | POPA, ILEANA | 26d overdue |
| 18627691 | SYSTEMS AND METHODS FOR FACILITATING LESION INSPECTION AND ANALYSIS | BEKELE, MEKONEN T | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
| 18219325 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES AT A BINDING INTERFACE | FRUMKIN, JESSE P | 26d overdue |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | GONZALES, JOSEPHINE MARIA | 4d overdue |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | — |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | FERGUSON SAMRETH, MARISSA LIANA | — |
| 19039502 | SYSTEMS AND METHODS FOR MEASUREMENT AND CONTROL OF SPRAYED LIQUID COVERAGE ON PLANT SURFACES | YANG, JIANXUN | — |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | KONVES, ADRIANNA N | — |
| Art Unit | Apps |
|---|---|
| 1684 | 5 |
| 1638 | 3 |
| 1636 | 3 |
| 1685 | 3 |
| 1633 | 3 |
| 1699 | 2 |
| 1653 | 2 |
| 1615 | 2 |
| 1623 | 2 |
| 1613 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | Tract Pharmaceuticals, Inc. | JARRELL, NOBLE E | 1699 | §103§112 | Final Rejection | — | Pending | Aug 25, 2025 |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | X-Celeprint Limited | FERGUSON SAMRETH, MARISSA LIANA | 2853 | §103 | Non-Final OA | — | Pending | Jul 29, 2025 |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | Helix Nanotechnologies Inc. | GONZALES, JOSEPHINE MARIA | 1631 | §103§112 | Final Rejection | 4d overdue | Pending | Jul 17, 2025 |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | Marvelbiome, Inc. | BREEN, KIMBERLY CATHERINE | 1653 | §101§102§103§112Other | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 19039502 | SYSTEMS AND METHODS FOR MEASUREMENT AND CONTROL OF SPRAYED LIQUID COVERAGE ON PLANT SURFACES | Agzen Inc. | YANG, JIANXUN | §103 | Non-Final OA | — | Pending | Jan 28, 2025 | |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | X-Celeprint Limited | KONVES, ADRIANNA N | 1748 | §102§103Other | Final Rejection | — | Pending | Dec 20, 2024 |
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | Claw Biotech Holdings, LLC | TRAN, SUSAN T | 1615 | §102§112Other | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18873573 | NUTRACEUTICAL PARTICLES | Vitakey Inc. | BOATENG, AFUA BAMFOAA | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18946253 | ELECTRONIC STETHOSCOPE AND DIAGNOSTIC ALGORITHM | Korion Health Inc. | ZHU, QIN | 2691 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18883913 | GENERATION OF ACYL AMINO ACIDS | Modular Genetics, Inc. | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18841541 | FOLDABLE PHYSICAL STRUCTURES | University Of Maine System Board Of Trustees | HIJAZ, OMAR F | 3635 | §102§103 | Final Rejection | — | Pending | Aug 26, 2024 |
| 18835307 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Insight Molecular Diagnostics Inc. | EVANS, ASHLEY ELIZABETH | 3687 | §101 | Final Rejection | — | Pending | Aug 01, 2024 |
| 18728643 | WEARABLES, METHODS, AND SYSTEMS FOR ALERTING USERS TO HEALTH EMERGENCIES | Echas LLC | MINCHELLA, ADAM ZACHARY | 3794 | §102§103§112 | Non-Final OA | 22d | Pending | Jul 12, 2024 |
| 18771086 | ENCLOSED CAVITY STRUCTURES | X-Celeprint Limited | ARROYO, TERESA M | 2893 | §102§103 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18726861 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Lawrence Livermore National Security, LLC | AGGARWAL, SAHIL CHANDER | 1623 | §112DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18721531 | RUMINANT FEED OR SUPPLEMENT FOR RUMINANT FEED AND PROCESS FOR PREPARING THE SAME | Borregaard AS | GWARTNEY, ELIZABETH A | 1759 | §103 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | Libertas Bio, Inc. | ROSENTHAL, ANDREW S | 1613 | §103§112 | Final Rejection | 70d overdue | Pending | May 20, 2024 |
| 18710074 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | AULAKH, CHARANJIT | 1629 | §112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18627691 | SYSTEMS AND METHODS FOR FACILITATING LESION INSPECTION AND ANALYSIS | Exini Diagnostics AB | BEKELE, MEKONEN T | 2699 | §102§103 | Final Rejection | 17d overdue | Pending | Apr 05, 2024 |
| 18611068 | DETECTION OF COLORECTAL CANCER | Universal Diagnostics, S.A. | MUMMERT, STEPHANIE KANE | 1637 | §102 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18593039 | TRANSFER-PRINTABLE MICRO-OPTICAL STRUCTURES | X-Celeprint Limited | PENG, CHARLIE YU | 2874 | §102§103 | Final Rejection | — | Pending | Mar 01, 2024 |
| 18584370 | PATTERNED ADHESIVE IN CAVITIES FOR MICRO-TRANSFER PRINTING | X-Celeprint Limited | VALENZUELA, PATRICIA D | 2812 | §103 | Final Rejection | — | Pending | Feb 22, 2024 |
| 18682205 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF | Adimab, LLC | VAN DRUFF, SYDNEY | 1643 | §102§112DP | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18294825 | CELLULOSE NANOFIBER (CNF) STABILIZED MEMBRANES AND METHODS OF MAKING THEREOF | University Of Maine System Board Of Trustees | ORME, PATRICK JAMES | 1779 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18293884 | METHODS FOR REPAIRING CARTILAGE DEFECTS | Vericel Corporation | HU, ANN M | 3774 | §103 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18292859 | IMPROVED CRISPR-CAS TECHNOLOGIES | Sherlock Biosciences, Inc. | HANEY, AMANDA MARIE | 1682 | §102§103DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | TheRas, Inc. | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Jan 23, 2024 |
| 18576880 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Olema Pharmaceuticals, Inc. | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18576073 | METHODS | Genetix Biotherapeutics Inc. | TSUI, YUNG-SHENG M | 1684 | §102§103 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18390483 | MICRO-TRANSFER PRINTING METHODS | X-Celeprint Limited | KARIMY, TIMOR | 2818 | §102§103 | Final Rejection | — | Pending | Dec 20, 2023 |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | Editas Medicine, Inc. | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 12, 2023 |
| 18537611 | METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE | Pharmatrophix, Inc. | PARK, HAEJIN S | 1614 | §102§103§112DP | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. | FETTEROLF, BRANDON J | 1626 | §103DP | Final Rejection | 14d | Pending | Nov 21, 2023 |
| 18560651 | ADENOVIRAL HELPER PLASMID | Forge Biologics, Inc. | PARAS JR, PETER | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18285810 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. | WHITEMAN, BRIAN A | 1636 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18284959 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | Neoplants SAS | MCWILLIAMS, KELSEY LYNN | 1663 | §103§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18551741 | IMMUNE STIMULATING NANOPARTICLE COMPOSITION | Monta Biosciences Aps | ARNOLD, ERNST V | 1626 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18468681 | NOVEL RECOMBINASES AND METHODS OF USE | Editas Medicine, Inc. | YU, DELPHINUS DOU YI | 1636 | §102§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18244685 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | Marvelbiome, Inc. | EDWARDS, JESSICA FAYE | 1657 | §112DP | Final Rejection | 5d overdue | Pending | Sep 11, 2023 |
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | Claw Biotech Holdings, LLC | KIM, DANIELLE A | 1613 | §103DP | Final Rejection | 10d overdue | Pending | Aug 16, 2023 |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | Sherlock Biosciences, Inc. | BAUSCH, SARAE L | 1699 | §102§112 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18274754 | CANCER THERAPY | Surge Therapeutics, Inc. | YANG, TIAN | 1674 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18224842 | METHODS OF ALTERING PROTEIN DEPOSITION ON URINARY CATHETERS AND DEVICES | UNIVERSITY OF NOTRE DAME DU LAC | WIECZOREK, MICHAEL P | 1712 | §102§103 | Final Rejection | 26d | Pending | Jul 21, 2023 |
| 18219325 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES AT A BINDING INTERFACE | Pythia Labs, Inc. | FRUMKIN, JESSE P | 1685 | §102 | Final Rejection | 26d overdue | Pending | Jul 07, 2023 |
| 18345163 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami'S Research Laboratory, Pvt. Ltd. | KIM, YUNSOO | 1641 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18216172 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES | Pythia Labs, Inc. | FRUMKIN, JESSE P | 1685 | §102§112DP | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18268578 | TAXONOMY-INDEPENDENT CANCER DIAGNOSTICS AND CLASSIFICATION USING MICROBIAL NUCLEIC ACIDS AND SOMATIC MUTATIONS | Universal Diagnostics, S.A. | AUGER, NOAH ANDREW | 1687 | §101§103§112 | Final Rejection | 34d | Pending | Jun 20, 2023 |
| 18252709 | CANCER DIAGNOSIS AND CLASSIFICATION BY NON-HUMAN METAGENOMIC PATHWAY ANALYSIS | Universal Diagnostics, S.A. | WISE, OLIVIA M. | 1685 | §101§103§112 | Non-Final OA | — | Pending | May 11, 2023 |
| 18035683 | METHODS | Genetix Biotherapeutics Inc. | WESTON, ALYSSA G | 1633 | §102 | Non-Final OA | 62d | Pending | May 05, 2023 |
| 18142068 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. | RODRIGUEZ, RAYNA B | 1628 | Other | Non-Final OA | 62d | Pending | May 02, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.4% of resolved applications prosecuted by Choate, Hall & Stewart LLP were allowed, across 6,127 applications in USPTO records.
3.57 office actions per allowed application on average.
87 pending office actions as of October 2026, for 53 clients, before 83 examiners in 57 art units.
